Further tests of these FAK inhibitors (3 or 5 μM) combined with crizotinib or entrectinib (30 μM to 4.572 nM) resulted in the dose-dependent inhibition of cancer cell growth in non-resistant CDH1-deficient cell lines that was stronger than either monotherapy (Figure 2 A-F, Figure S2 F-U). The gene discussed is CDH1; the disease is cancer.